查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1606307

癌症基因治疗市场：按治疗方法、适应症和应用分类 - 全球预测 2025-2030

Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Gene Transfer, Oncolytic Virotherapy), Indication (Breast Cancer, Liver Cancer, Lung Cancer), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症基因治疗市值为22亿美元，预计2024年将达27.5亿美元，复合年增长率为20.22%，预计到2030年将达到79.9亿美元。

癌症基因治疗是一种创新方法，旨在透过改变人体细胞内的遗传指令来治疗或预防癌症。这种治疗方法包括插入有故障的基因的健康副本，敲除导致问题的基因，或引入新的基因来帮助对抗疾病。癌症基因治疗的需求在于其提供个人化治疗选择、提高存活率并减少传统癌症治疗常见的全身性副作用的潜力。其应用多种多样，主要包括精准肿瘤学、标靶药物传递和再生医学。最终用户涵盖医院、诊所和研究机构，凸显了该市场的广泛范围。

主要市场统计
基准年[2023] 22亿美元
预测年份 [2024] 27.5亿美元
预测年份 [2030] 79.9亿美元
复合年增长率（%） 20.22%

基因工程技术的进步、基因组研究资金的增加以及个人化医疗意识的增强推动了癌症基因治疗市场的成长。 CRISPR-Cas9和其他先进基因编辑工具的发展正在扩大潜在的应用，并使基因疗法更容易和有效。此外，全球癌症发生率的上升和传统治疗方法的限制使得对创新解决方案的需求持续存在。然而，高成本、监管障碍、伦理问题以及基因治疗的复杂性等挑战成为市场成长的障碍。

随着研发投资的增加，机会无所不在，特别是关注 RNA 引导基因编辑和 CAR T 细胞疗法的潜力。生物技术公司和学术机构之间的合作促进创新。市场相关人员应专注于宣传活动，并与医疗保健系统建立强大的合作伙伴关係，以推动市场渗透。公司还可以探索成本分摊和风险缓解策略的伙伴关係，以克服财务障碍。然而，持续警惕潜在的副作用并谨慎处理道德问题对于永续成长至关重要。在创新的引领下，癌症基因治疗市场即将成长，需要持续的研究、策略联盟和强大的法律规范来释放其全部潜力。

市场动态：快速发展的癌症基因治疗市场的关键市场洞察

供需的动态交互作用正在改变癌症基因治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 需要寻找治疗方案来解决癌症盛行率日益上升的问题
    • 活性化研发活动以振兴癌症研究
    • 政府支持癌症治疗方法和基因疗法的发展
  • 市场限制因素
    • 副作用和产品召回的风险
  • 市场机会
    • 基因治疗癌症中心的全球扩张
    • 使用人工智慧和机器学习加速细胞和基因治疗
  • 市场挑战
    • 基因治疗安全性的监管考虑

波特五力：驾驭癌症基因治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症基因治疗市场的外部影响

外部宏观环境因素在塑造癌症基因治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症基因治疗市场的竞争格局

对癌症基因治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵癌症基因治疗市场供应商绩效评估

FPNV定位矩阵是评估癌症基因治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了癌症基因治疗市场的成功之路

癌症基因治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 需要治疗方法来解决日益增加的癌症发生率
      • 加强研发活动以刺激癌症研究
      • 政府支持癌症治疗方法和基因疗法的发展
    • 抑制因素
      • 不良免疫反应和产品回想的风险
    • 机会
      • 扩大基因治疗癌症中心的世界
      • 使用 AI 和 ML 加速细胞和基因治疗
    • 任务
      • 基因治疗安全性的监管考虑
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症基因治疗市场：依治疗方法

  • 基因诱导的免疫治疗
  • 基因转移
  • 溶瘤病毒疗法

第七章癌症基因治疗市场：依适应症分类

  • 乳癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 摄护腺癌

第八章癌症基因治疗市场：依最终用途分类

  • 生物製药公司
  • 诊断中心
  • 肿瘤研究所

第九章美洲癌症基因治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太癌症基因治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的癌症基因治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Achieve Life Sciences, Inc.
  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics Inc.
  • Amgen, Inc.
  • Bayer AG
  • Biogen Inc.
  • Bluebird Bio Inc.
  • Bristol-Myers Squibb Company
  • Candel Therapeutics
  • Elevate Bio Inc.
  • Genelux Corporation
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Inc.
  • ImmunityBio, Inc.
  • Merck KGaA
  • Precigen, Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market was valued at USD 2.20 billion in 2023, expected to reach USD 2.75 billion in 2024, and is projected to grow at a CAGR of 20.22%, to USD 7.99 billion by 2030.

Cancer gene therapy is a revolutionary approach that aims to treat or prevent cancer by altering the genetic instructions within a person's cells. This therapy involves methods like inserting a healthy copy of a malfunctioning gene, knocking out a gene that's causing issues, or introducing a new gene to help fight the disease. The necessity for cancer gene therapy lies in its potential to provide personalized treatment options, improve survival rates, and reduce the systemic side effects commonly associated with traditional cancer treatments. Its applications are diverse and primarily include precision oncology, targeted drug delivery, and regenerative medicine. End-users span across hospitals, clinics, and research institutes, highlighting the vast scope of this market.

KEY MARKET STATISTICS
Base Year [2023] USD 2.20 billion
Estimated Year [2024] USD 2.75 billion
Forecast Year [2030] USD 7.99 billion
CAGR (%) 20.22%

The market growth of cancer gene therapy is driven by advancements in genetic engineering technologies, increased funding for genomic research, and rising awareness regarding personalized medicine. The development of CRISPR-Cas9 and other advanced gene-editing tools has expanded potential applications, making gene therapy more accessible and effective. Moreover, the increasing incidence of cancer globally and the limitations of conventional treatments perpetuate the demand for innovative solutions. However, challenges, including high costs, regulatory hurdles, ethical concerns, and the complex nature of gene therapy, pose barriers to market growth.

Opportunities are ripe in expanding research and development investments, especially focusing on the latent potential of RNA-guided gene editing and CAR T-cell therapies. Collaborative efforts between biotech firms and academic institutions can foster innovation. Market players should focus on awareness campaigns and build strong alliances with healthcare systems to expedite market penetration. Businesses can also explore partnerships for cost-sharing and risk mitigation strategies to overcome financial barriers. However, ongoing vigilance for potential side effects and carefully navigating the ethical landscape is crucial for sustainable growth. The cancer gene therapy market is poised for growth, with innovation at the helm, necessitating continuous research, strategic alliances, and robust regulatory frameworks to maximize market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Gene Therapy Market

The Cancer Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for treatment options to tackle the growing prevalence of cancers
    • Increasing R&D activities to stimulate cancer research
    • Government support for the development of cancer treatment methods and gene therapy
  • Market Restraints
    • Risk of adverse immune reaction and recall of products
  • Market Opportunities
    • Expansion of gene therapy cancer centers worldwide
    • Utilization of AI and ML to accelerate cell and gene therapies
  • Market Challenges
    • Regulatory considerations concerning the safety of gene therapy

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Gene Therapy Market

A detailed market share analysis in the Cancer Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Gene Therapy Market

A strategic analysis of the Cancer Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Achieve Life Sciences, Inc., Adaptimmune Therapeutics PLC, Alaunos Therapeutics Inc., Amgen, Inc., Bayer AG, Biogen Inc., Bluebird Bio Inc., Bristol-Myers Squibb Company, Candel Therapeutics, Elevate Bio Inc., Genelux Corporation, Gilead Sciences, Inc., GlaxoSmithKline Inc., ImmunityBio, Inc., Merck KGaA, Precigen, Inc., Sarepta Therapeutics, Inc., Shanghai Sunway Biotech Co., Ltd., and Sibiono GeneTech Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Gene Induced Immunotherapy, Gene Transfer, and Oncolytic Virotherapy.
  • Based on Indication, market is studied across Breast Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on End-Use, market is studied across Biopharmaceutical Companies, Diagnostic Centers, and Oncology Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for treatment options to tackle the growing prevalence of cancers
      • 5.1.1.2. Increasing R&D activities to stimulate cancer research
      • 5.1.1.3. Government support for the development of cancer treatment methods and gene therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of adverse immune reaction and recall of products
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of gene therapy cancer centers worldwide
      • 5.1.3.2. Utilization of AI and ML to accelerate cell and gene therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory considerations concerning the safety of gene therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Gene Therapy Market, by Therapy

  • 6.1. Introduction
  • 6.2. Gene Induced Immunotherapy
  • 6.3. Gene Transfer
  • 6.4. Oncolytic Virotherapy

7. Cancer Gene Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Liver Cancer
  • 7.4. Lung Cancer
  • 7.5. Ovarian Cancer
  • 7.6. Pancreatic Cancer
  • 7.7. Prostate Cancer

8. Cancer Gene Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biopharmaceutical Companies
  • 8.3. Diagnostic Centers
  • 8.4. Oncology Research Institutes

9. Americas Cancer Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Achieve Life Sciences, Inc.
  • 3. Adaptimmune Therapeutics PLC
  • 4. Alaunos Therapeutics Inc.
  • 5. Amgen, Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bluebird Bio Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Candel Therapeutics
  • 11. Elevate Bio Inc.
  • 12. Genelux Corporation
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline Inc.
  • 15. ImmunityBio, Inc.
  • 16. Merck KGaA
  • 17. Precigen, Inc.
  • 18. Sarepta Therapeutics, Inc.
  • 19. Shanghai Sunway Biotech Co., Ltd.
  • 20. Sibiono GeneTech Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE INDUCED IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GENE TRANSFER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023